Overview
Paresh Kumar is of counsel in the Life Sciences Transactions practice at Paul Hastings and is based in Boston. He brings a hybrid clinical, financial and legal perspective to advising life sciences companies and investors on strategic transactions and corporate matters.
Paresh has over a decade of experience across venture capital, private equity, pharmaceutical R&D finance and legal practice. He has served as an investor with board observer roles at multiple biotech companies and worked in R&D finance at a global pharmaceutical company. He supports executive teams and boards on deal strategy, valuation and risk allocation across corporate and IP driven transactions for companies ranging from venture backed preclinical biotechs to commercial stage biopharma.
His work focuses on high impact transactions, including R&D collaborations, licensing and option arrangements, joint ventures, M&A, commercial agreements and structured financings such as equity, convertible debt, credit facilities and royalty transactions. He works closely with cross-functional teams across legal, business development, finance and technical departments to execute these matters.
Paresh advises senior leadership and boards across the product development lifecycle. He frames complex issues, drives decision-making and converts scientific and financial inputs into actionable legal and business strategies.
Accolades
- Ones to Watch, Intellectual Property Law, Best Lawyers
Education
- Boston University School of Law, J.D., 2018
- Northeastern University, Pharm.D., 2014
- Northeastern University, B.S., 2013
Representations
- Isomorphic Labs in its strategic research collaboration with Novartis to discover small molecule therapeutics against three undisclosed targets.
- Septerna in an asset sale to Vertex Pharmaceuticals for an undisclosed program from its GPCR Native Complex platform.
- bit.bio in its collaboration and option agreement with BlueRock Therapeutics, a Bayer subsidiary, for the discovery and manufacture of iPSC-derived regulatory T cell therapies.
- Moderna in its strategic collaboration with Generation Bio to develop non-viral genetic medicines.
- Moderna in its strategic collaboration with Life Edit Therapeutics to accelerate the development of novel in vivo gene editing therapies.
- Disc Medicine in its exclusive license agreement with Mabwell Therapeutics for certain rights to a portfolio of TMPRSS6-targeting antibody candidates.
- AbCellera in its strategic alliance with Rallybio to discover, develop and commercialize novel antibody-based therapeutics for rare diseases.
- Envisagenics in its research collaboration with Bristol Myers Squibb to identify alternative splicing-derived oncology targets.
- ProQR Therapeutics in its global licensing and research collaboration with Eli Lilly focused on RNA editing medicines for genetic disorders in the liver and nervous system.
- Acadia Pharmaceuticals in its collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for severe and rare neurodevelopmental diseases.
- Concert Pharmaceuticals in its sale to BVF Partners and RA Capital Management of an interest in potential future royalties on sales of AVP-786.
- Moderna in its strategic research and development collaboration with Metagenomi to develop next-generation in vivo gene editing therapeutics.
- Exicure in its exclusive collaboration with Ipsen to research, develop and commercialize novel spherical nucleic acids for rare neurodegenerative disorders.
- Trillium Therapeutics in its acquisition by Pfizer.
- LEXEO Therapeutics in its acquisition of Stelios Therapeutics and its gene therapy programs for rare cardiovascular diseases.
- Moderna in its COVID-19 vaccine supply agreements with governments worldwide.
- Represented several biotechnology companies in their companion diagnostic (CDx) agreements with Foundation Medicine
Represented numerous biotechnology companies in IP licensing agreements from leading scientific and medical research institutions around the world
Matters may have been handled prior to joining Paul Hastings
Engagement & Publications
- Investor Panel, Chardan Genetic Medicines Conference, Speaker (October 2025)
- Smart Capital Panel, LSX Congress USA, Speaker (September 2025)
- Capital Markets Panel, BioEquity Europe, Speaker (May 2025)
- Northeastern University Graduate Ceremony, Alumni Commencement Speaker (May 2023)